Table 3.
Comparison of the distribution of MCP1 rs1024611 polymorphic variants in anti-HBc positive/anti-HBs negative hemodialysis (HD) and controls
| Genotype | Anti-HBc positive/anti-HBs negative HD patients (frequency) | Controls (frequency) | Odds ratio (95%CI) | Two-tailed P | Ptrend | Pgenotyping | Power (%) |
|---|---|---|---|---|---|---|---|
| All HD cases vs. controls | |||||||
| n=43 | n=437 | ||||||
| AA | 20 (0.47) | 225 (0.51) | Referent | – | 0.402 | 0.663 | |
| AG | 18 (0.42) | 177 (0.41) | 1.144 (0.552–2.354) | 0.818 | 5.6 | ||
| GG | 5 (0.11) | 35 (0.08) | 1.607 (0.442–4.796) | 0.525 | 13.3 | ||
| AG+GG | 23 (0.53) | 212 (0.49) | 1.221 (0.621–2.417) | 0.643 | 7.5 | ||
| MAF | 28 (0.32) | 247 (0.28) | 1.225 (0.733–2.008) | 0.470 | 13.1 | ||
| HD cases without DM vs. controls | |||||||
| n=32 | n=437 | ||||||
| AA | 16 (0.50) | 225 (0.51) | Referent | – | 0.611 | 0.669 | |
| AG | 12 (0.38) | 177 (0.41) | 0.953 (0.401–2.211) | 1.000 | 4.5 | ||
| GG | 4 (0.13) | 35 (0.08) | 1.607 (0.369–5.374) | 0.595 | 13.4 | ||
| AG+GG | 16 (0.50) | 212 (0.49) | 1.061 (0.483–2.330) | 1.000 | 4.6 | ||
| MAF | 20 (0.31) | 247 (0.28) | 1.154 (0.631–2.046) | 0.702 | 7.3 | ||
| HD cases with DM vs. controls | |||||||
| n=37 | n=437 | ||||||
| AA | 4 (0.36) | 225 (0.51) | Referent | – | 0.405 | 0.602 | |
| AG | 6 (0.55) | 177 (0.41) | 1.907 (0.444–9.317) | 0.494 | 13.9 | ||
| GG | 1 (0.09) | 35 (0.08) | 1.607 (0.032–16.83) | 1.000 | 5.7 | ||
| AG+GG | 7 (0.64) | 212 (0.49) | 1.857 (0.464–8.767) | 0.494 | 12.2 | ||
| MAF | 8 (0.36) | 247 (0.28) | 1.451 (0.520–3.758) | 0.540 | 11.5 | ||
anti-HBc – antibodies to core antigen of hepatitis B virus; anti-HBs – antibodies to surface antigen of hepatitis B virus; DM – diabetes mellitus; MAF – minor allele frequency.